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Poster Session II S3472 - 41).The cumulative incidence(CI) of severe acute GvHD(grade
II-IV) was 7% at 100 days.3-yr CI of chronic GvHD was 25%.3-
yr OS and PFS was 69% and 66% for sibling vs 42%(p 5 0.08)
and 41%(p 5 0.14) for unrelated donors.3-yr NRM and RR was
14% and 25% for sibling vs 31%(p 5 0.15) and 28%(p 5 0.27) for
unrelated donors.Outcomes for patients who had high-risk(HR) fea-
tures prior to transplant(poor risk cytogenetics,FLT3 ITD muta-
tion,previous MDS,secondary AML) were compared to outcomes
of those with standard risk(SR) disease.The HR group(n 5 37) had
OS and PFS at 3 yrs of 50% and 47% vs 60%(p 5 0.13) and
60%(p 5 0.1) for SR group(n 5 33).3-yr NRM and RR was 21%
and 25% in the HR group vs 23%(p 5 0.19) and 24%(p 5 0.18)
in the SR group(p 5 0.19).The 23 patients $60 yrs(20 unrelated
and/or HR) had a 3 yr OS of 38% and PFS of 38%. In conclusion,
many patients withHRAMLwho attain CRmaintain durable remis-
sions following RIC allo-HSCT with the FMC regimen. Although
outcomes are marginally less good than seen in patients with SR
AML receiving RIC transplant, they are much better than would
be achieved with current chemotherapy regimens.The low NRM
in sibling allo-HSCT together with the relatively low RR support
further exploration of FMC conditioned allo-HSCT in all patients
with SR AML with a matched sibling donor.
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Hematologic malignancy patients who are not referred by their
primary Hematologist or Medical Oncologist suffer disparate access
to allogeneic hematopoietic cell transplantation (HCT). However,
systematic investigation into physician, system, and patient factors
relevant to this decision making is lacking. Accordingly, we surveyed
a nationally representative random sample of practicing Hematolo-
gists/Medical Oncologists identified through the AMA Masterfile.
The survey content was organized in three sections: (I) Vignette
based decision making according to best-worst scaling; (II) examina-
tion of physician, system and patient factors relevant to decision
making; and (III) respondent socio-demographic information. A
modified Dillman approach was utilized to encourage survey re-
sponse rate. From 1,200 surveyed, a total of 113 physicians
responded. Of these, 68% were male, 62% identified as White/
non-Hispanic, 79% practiced in non-academic settings, and 80% re-
ported spending 75-100% of their professional effort in clinical care.
From best-worst scaling data provided by physicians in response to
clinical vignettes, we detected significantly increased odds for non-
HCT referral according to age (age 60 vs. 30, OR 8.3, 95% CI
5.9-11.7, p\ 0.0001), race (African American vs. Caucasian, OR
2.4, 95%CI 1.9-2.9, p\0.0001), and insurance coverage (no cover-
age vs. coverage, OR 6.9, 95%CI 5.2-9.1, p\ 0.0001). Four attri-
bute-specific Wald tests reject equivalence in odds ratios across the
four diseases (MDS, ALL, CML, AML) at a p-value less than 0.05,
indicating condition-specific variability. Physician (perception of
HCT risks), system (insurance coverage), and patient (age, social
support, co-morbid illness) factors were strongly endorsed by re-
spondents as important determinants of their HCT referral prac-
tices. The majority (64%) of physicians indicated that patients do
not have equal access to HCT consultation. Qualitative comments
provided even greater clarity to perceived barriers to HCT referral,
largely focused on lack of insurance coverage and need for increased
education of practicing Hematologists/Medical Oncologists on tim-
ing and indication for HCT referral. These data speak to important
factors relevant to HCT referral practices, and highlight several op-
portunities for education and intervention to reduce current dispar-
ities in access to HCT.
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Therapy related acute myeloid leukemia (t-AML) and myelodys-
plastic syndrome (t-MDS) have poor outcomes with conventional
chemotherapy. The only curative treatment is allogeneic hematopoi-
etic cell transplantation (HCT). Secondary AML evolving from
MDS (s-AML) has a similar poor prognosis with conventional anti-
leukemia therapies.
In this retrospective study, the transplant outcomes of 91 adult pa-
tients with t-AML (n 5 19), t-MDS (n 5 19) and s-AML (n 5 53)
treated with allogeneic HCT at OHSU from January 1997 to De-
cember 2010 were assessed.
Themedian age of patientswas 55 years (range: 21-72).Median age
for t-AML, t-MDS, and s-AMLwas 51, 59, and 56 years, respectively.
Poor risk cytogenetics were found in 18% of t-MDS pts and 38% of
the AML pts. Donors were mostly matched unrelated (61%), and
a myeloablative regimen was used for conditioning in 68% of the pa-
tients. Two-yearoverall survival (OS) and relapse incidencewere 44%
and 43%, respectively, for all cohorts. NRMwas 13% at 100 days and
33% at 2 years. s-AML patients had significantly improved OS com-
pared to t-AML and t-MDS patients (HR5 0.5, p5 0.02).
Four adverse risk factors impact on DFS and OS in t-AML/MDS
pts (Litzow, Blood 2010). Outcomes in our s-AML patients were as-
sessed for these factors: age . 35 years; poor-risk cytogenetics; t-
AML not in remission or advanced t-MDS; and donor other than
an HLA-identical sibling or a partially or well-matched unrelated
donor. One-year event-free survival for our subjects with 0-1, 2, or
3-4 of these risk factors was 83%, 63%, and 34%, respectively
(p5 0.01), but OS was not different (p5 0.28). However, pre-trans-
plant KPS # 80; intermediate or poor cytogenetics; and URD mis-
matched or other relative donor impacted with one-year OS for
subjects with 1, 2, or 3 of these risk factors 5 62%, 24%, and
33%, respectively (p 5 0.04).
In conclusion, the CIBMTR scoring system for t-AML/MDS was
not fully validated in our t-MDS, t-AML, and s-AML patients, but
appeared overall consistent.
However, performance status, rather than age, was more predic-
tive for OS.
Also, s-AML had improved OS compared to t-AML and t-MDS
patients, suggesting that these are biologically different diseases.
These data also indicate the need for the identification of prognos-
tic factors for secondary AML/MDS patients, to permit accurate
prediction of allogeneic HCT outcomes in this unique patient
population.
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Advanced age has been associated with higher mortality after mye-
loablative (MA) allogeneic hematopoietic cell transplantation
(HCT). Reduced intensity conditioning (RIC) and non myeloabla-
tive (NM) regimens have been developed to expand allogeneic
HCT to the aging population. A retrospective analysis of patients
aged 60 and older was performed and outcome of patients trans-
planted with MA, RIC and NM regimens were assessed.
159 patients transplanted between January 1998 and December
2010 for hematological malignancies were analyzed. 41 patients un-
derwent MA, 100 patients underwent RIC and 18 patients under-
went NM conditioned HCT. 62 patients (39%) had a matched
related donor, 67 (42%) had a matched unrelated donor and 30
(19%) had a mismatch donor HCT.
Overall survival (OS) was significantly influenced by conditioning
regimen (p 5 0.03). One year OS was 59%, 30% and 28% for RIC,
NM and MA group respectively. 3 year OS was significantly better
for RIC at 26% vs. 15% for MA (p5 0.02). There was no significant
difference in the progression free survival (PFS) and relapse rate be-
tween the three groups. There was trend towards significance for
non relapse mortality (NRM) based on conditioning regimen (p 5
0.07) and 100 day NRM was 11%, 3.5% and 6% for MA, RIC and
NM respectively.
